Revenue Growth: HEPLISAV-B net product revenue surged by 69% year-over-year to $213 million in 2023. Market Leadership: Achieved market leader status in retail pharmacy and IDNs, with U.S. market share rising to approximately 42%. 2024 Outlook: HEPLISAV-B net product revenue projected to be $265 - $280 million; company expects to be cash flow positive.
Q4 2023 revenue of $42.8 million
Q4 2023 Adjusted EBITDA of $4.1 million
Fourth consecutive quarter of positive Adjusted EBITDA with $16.7 million in positive Adjusted EBITDA in 2023
Philip.
Inseego Corp. (the "Company"), a technology leader in 5G and 4G mobile and fixed wireless solutions for mobile network operators, Fortune 500 enterprises, SMBs, and consumers, today reported its results for the fourth quarter and year ended December.